ArticleThe Journal of infectious diseases2011
The necessity and quandaries of dengue vaccine development.
Article in The Journal of infectious diseases, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults.The American journal of tropical medicine and hygiene · 2013Trial
- Fully automated high-throughput immuno-µPlaque assay for live-attenuated tetravalent dengue vaccine development.Frontiers in immunology · 2024Article
- Article
- Recombinant Dengue Virus 4 Envelope Glycoprotein Virus-Like Particles Derived from Pichia pastoris are Capable of Eliciting Homotypic Domain III-Directed Neutralizing Antibodies.The American journal of tropical medicine and hygiene · 2017Article
- Article
- Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies.BMC biotechnology · 2016Article
- Cross-protection induced by Japanese encephalitis vaccines against different genotypes of Dengue viruses in mice.Scientific reports · 2016Article
- Recombinant Dengue 2 Virus NS3 Helicase Protein Enhances Antibody and T-Cell Response of Purified Inactivated Vaccine.PloS one · 2016Article
- Safety and Immunogenicity of a Dengue Virus Serotype-1 Purified-Inactivated Vaccine: Results of a Phase 1 Clinical Trial.The American journal of tropical medicine and hygiene · 2015Article
- Improving dengue virus capture rates in humans and vectors in Kamphaeng Phet Province, Thailand, using an enhanced spatiotemporal surveillance strategy.The American journal of tropical medicine and hygiene · 2015Article
- Pichia pastoris-expressed dengue 3 envelope-based virus-like particles elicit predominantly domain III-focused high titer neutralizing antibodies.Frontiers in microbiology · 2015Article
- Recent progress in dengue vaccine development.Virologica Sinica · 2014Review
- Emerging and reemerging neglected tropical diseases: a review of key characteristics, risk factors, and the policy and innovation environment.Clinical microbiology reviews · 2014Review
- Dengue human infection model: introduction.The Journal of infectious diseases · 2014Article
- Dengue vaccine: a valuable asset for the future.Human vaccines & immunotherapeutics · 2014Article
- Article
- Role of microparticles in dengue virus infection and its impact on medical intervention strategies.The Yale journal of biology and medicine · 2012Review
- Sculpting humoral immunity through dengue vaccination to enhance protective immunity.Frontiers in immunology · 2012Article
- Treatment of dengue fever.Infection and drug resistance · 2012Article
- Immunization in travel medicine.Primary care · 2011Review
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.